#ThrowbackThursday to our 2025 faculty group picture moment at the inaugural Nashville Hematology Conference. We’re grateful for our chairs, Drs. drjoannarhodes, Jesus Berdeja, MD, and the expert faculty for their collaboration and energy that made this year’s meeting so memorable.

60 reasons to attend #NashvilleHeme26 on Feb 26-28, 2026: 60+ Expert Faculty 🤩 and 60% off early registration with code NHC26X Join us Feb 26-28, 2026 in Nashville, TN: hubs.la/Q03RBHF80 Jesus Berdeja, MD drjoannarhodes Andrew Kuykendall MD #MedEd #CME #hematology

Trainees & junior faculty: the #TexasLung26 Poster Competition is open - winners will receive registration, travel, and accommodation to the 2026 Texas Lung Cancer Conference at Austin City Limits, April 9-11, 2026. Submit today! Details at thetlcconference.com/poster-competi…

Today we celebrate a new partnership and are looking forward to bringing customized medical education to Rocky Mountain Cancer Centers' healthcare providers. View the press release: na2.hubs.ly/H022Y6Q0

The Lockwood Group, Research To Practice, and IDEOlogy Health are joining forces to elevate the way medical education is delivered. We couldn’t be more excited to work alongside the brilliant team at RTP to deliver meaningful content for physicians and the partners who support

3 more months until #NashvilleHeme26! Join us on Feb 26-28, 2026 in Nashville, TN and receive up to 12 CE credits. Register today with 60% off early registration using code NHC26X 👉 na2.hubs.ly/H025h710 Jesus Berdeja, MD drjoannarhodes Andrew Kuykendall MD #MedEd #CME #hematology

🎉 The Nashville Hematology Conference has been recognized by @BizBashh as one of the “Most Innovative Meetings of 2025.” This award reflects the incredible work of our faculty, our dedicated 2025 chairs Drs. Jesus Berdeja, MD & drjoannarhodes, and our creative production team who

Time's running out to submit your abstracts to the #TexasLung26 Poster Competition! Submit by Nov 28th for a chance to win and be a part of the 4th annual 2-day CE-accredited #TexasLung26 conference in Austin, TX, April 9-11, 2026. Encores are welcomed and encouraged. View

Curious how advances in benign hematology can transform your practice? At 2-day CE-accredited #NashvilleHeme26 conference, join top experts Drs. Jennifer Green, Spero Cataland, Michelle Chi, Adam Cuker MD, MS, Scott Peslak, and Angela Weyward in Nashville, Feb 26–28, 2026. Early bird bonus:

IDEO Xchange: In REASON real-world study, 35% of NSCLC pts onneoadj IO + chem0o did not proceed to surgery. In your experience, what % of pts fail to reach surgery?

IDEO Xchange: For NSCLC patients receiving neoadj IO + chemo,what is most common reason pts at your institution DO NOTundergo surgery?

IDEO Xchange: What’s your preferred approach to treatmentintensification for 1L EGFR+ NSCLC?

IDEO Xchange: FLAURA2 poor prognosis subgrp data indicate OS benefit across baseline CNS/bone/liver mets and adverse EGFR/TP53 profiles. ​ ​ How likely are you to use osi+chemo as 1L standard for these pts?

IDEO Xchange: When a patient with non-AGA NSCLC develops oligoprogressive disease on systemic therapy, what is your usual approach?

IDEO Xchange: What is your preferred 1L therapy for a patient with mNSCLC with PD-L1 20% and STK11 and KEAP1 mutations?

IDEO Xchange: How would you sequence HER2-directed therapies in a patient with mNSCLC?